Cartalax (AED): what the research shows
- By Reed Calder
- Last reviewed Nov 12, 2026
- 21 studies and official documents checked
In short
Cartalax is a lab-made peptide of three amino acids (Ala-Glu-Asp, or AED) from the St. Petersburg group of Vladimir Khavinson. It is sold online for joints, cartilage and aging. The ten studies we found are in cells and rats: cartilage-protein and aging markers in cells in a dish, and urine output and protein in rats. We found no published study of it in people. A 2023 review by the developers’ group says older patients with osteoarthritis did well taking it by mouth, but its abstract cites no trial. Every study of it we found lists Linkova, Khavinson or both among its authors. It isn’t FDA-approved, and no registered trial lists it.
EvidenceCellAnimalHumanten studies, all from one research group; none in people
You’ll often read that Cartalax rebuilds cartilage, works only on cartilage, has no side effects and comes with a standard injection schedule. This page covers what it is, what each study tested, what the “cartilage-specific” label leaves out, and where it stands legally.
Names and forms you’ll see
| Name | What it is | Studied in people? |
|---|---|---|
| Cartalax, AED, Ala-Glu-Asp | The trade name, the one-letter code and the three-letter code for the same three amino acids (PubChem; Khavinson et al., 2021) | No study found |
| T-31 | A lab code for AED in a 2015 kidney-cell paper (Chalisova et al., 2015) | No study found |
| AEDG, Epitalon | A different peptide: four amino acids, AED plus glycine. Some pages write Cartalax as “AEDG,” which is Epitalon. See the Epitalon page | Yes, small studies, on its own page |
| Sigumir, cartilage polypeptide complex | An extract from animal cartilage made at the same institute: many short peptides, with AED one of them (Linkova et al., 2023; Myakisheva et al., 2023c) | One 2012 report of 62 patients; see below |
| Capsules, drops, injection vials | Forms sold online | No published study of any form |
CAS numbers
A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. The number is listed among the PubChem record’s names; we found no entry for it in the FDA’s substance registry.
| Form | CAS number | Registry record |
|---|---|---|
| Cartalax (Ala-Glu-Asp) | 85806-95-7 | PubChem |
What Cartalax is
Cartalax is three amino acids: alanine, glutamic acid and aspartic acid. Its formula is C12H19N3O8 and its weight about 333 (PubChem). It comes from Vladimir Khavinson’s group, which lists it for cartilage and skin cells (Khavinson et al., 2021).
The idea behind it is that very short peptides enter a cell’s nucleus and change which genes are switched on. For AED, what supports that is gene-activity changes in cells and a computer model of the peptide sitting in DNA (Khavinson et al., 2014). We found no direct test of it in a living body.
What has been studied
In people: nothing for AED alone
- No study of AED alone in people. We searched PubMed and ClinicalTrials.gov and found none (ClinicalTrials.gov search).
- A statement without a trial, 2023. A review by the developers’ group says Sigumir and AED (spelled “Kartalax” there) “showed high efficacy” in animal models of osteoarthritis and by mouth in older patients with it. The abstract names no study, group size or comparison, and we found no such paper (Myakisheva et al., 2023c).
- A cartilage extract, not AED alone, 2012. Sigumir was added to treatment in 62 older patients with jaw-joint disease. The authors reported short-term pain relief and wider mouth opening; the abstract describes no comparison group (Iordanishvili et al., 2012).
- A trial said to be running. The 2023 review of chondrogenic peptides says the cartilage extract is in phase 2 trials for osteoarthritis in Russia (Linkova et al., 2023). We found no registry record or result.
The only human report we found tested a cartilage extract, which holds many peptides, for a jaw-joint disease, and the developers’ own review is the source for the osteoarthritis claim.
EvidenceCellAnimalHumannothing in people for AED alone
In cells
- Human stem cells, cartilage markers, 2023. In aging human mesenchymal stem cells, AED at 200 ng/ml raised the activity and protein of SOX9, aggrecan, type II collagen and COMP, four markers of cartilage-building cells. The whole cartilage extract needed 2,000 ng/ml for the same effect (Myakisheva et al., 2023a).
- Aged cartilage cells, 2023. Aging chondrocytes made more p16, p21, p53, TNF-alpha and IL-1alpha and less Sirt1. AED moved these back toward normal (Myakisheva et al., 2023b).
- Skin cells, 2016 and 2020. In aging skin fibroblasts, AED lowered MMP-9, an enzyme that breaks down collagen and rises with age, raised two growth and renewal markers, and cut cell death (Lin'kova et al., 2016). In human skin fibroblasts it raised sirtuin-1, sirtuin-6 and collagen I (Fridman et al., 2020).
- Stem-cell genes, 2020. In human embryo bone-marrow stem cells at nanomolar concentrations, AED and two related peptides raised IGF1 gene activity 3.5 to 5.6 times. They also raised activity of the NF-kB gene, a switch that drives inflammation (Ashapkin et al., 2020).
- Kidney cells, 2014 and 2015. In aging kidney cell cultures, AED and a second tripeptide raised cell division, lowered p16, p21 and p53 and raised SIRT-6 (Khavinson et al., 2014). In kidney tissue cultures from young and old rats, AED stimulated division and lowered cell death, less than the whole kidney extract did (Chalisova et al., 2015).
- Cells that become neurons, 2019. A mix of four of the group’s peptides, AED among them, raised a nerve-growth marker in human tooth-ligament stem cells; the abstract doesn’t single out AED (Caputi et al., 2019).
EvidenceCellAnimalHuman
In rats
- Kidney injury, 2015. In rats with cisplatin-induced kidney failure, AED lowered protein and electrolytes in the urine. The kidney extract and two other peptides normalized more measures than AED did (Zamorskii et al., 2015).
- Old rats, 2018. AED raised urine output 1.2 to 1.4 times and cut urine protein 1.5 to 2.8 times. The authors saw no sign of kidney toxicity (Zamorskii et al., 2018).
Both rat studies are about kidneys, not joints. We found no paper on AED in a joint or arthritis model, although the 2023 review mentions positive ones.
EvidenceCellAnimalHuman
All ten studies above list Linkova, Khavinson or both among their authors, and we found no study of AED from a group without them. That isn’t proof of anything wrong, but nobody outside the group has been shown to repeat the results.
The usual claims, checked
| Claim | Verdict | What the studies found |
|---|---|---|
| It regrows or repairs cartilage | Untested | We found no study that measured cartilage in a person or animal after Cartalax. In human stem cells in a dish it raised the activity of cartilage-protein genes (Myakisheva et al., 2023a). A raised marker in a dish isn’t repair |
| It relieves joint pain or arthritis | Untested | We found no trial of it in people. A 2023 review by the developers’ group says older patients with osteoarthritis did well taking it by mouth, but gives no study or group size in its abstract (Myakisheva et al., 2023c) |
| It works only on cartilage | Contradicted | The studies also tested it in skin cells, kidney cells, rat kidneys and stem cells that become neurons (Fridman et al., 2020; Chalisova et al., 2015; Zamorskii et al., 2018; Caputi et al., 2019) |
| It cuts inflammation | Mixed | The signals differ. In aged cartilage cells it brought TNF-alpha and IL-1alpha back toward normal (Myakisheva et al., 2023b), but in human stem cells it raised activity of the NF-kB gene (Ashapkin et al., 2020). No test in people |
| It boosts collagen | Untested | In human skin cells in a dish it raised collagen I, and in human stem cells it raised type II collagen activity (Fridman et al., 2020; Myakisheva et al., 2023a). We found no test of collagen in anyone’s tissue |
| It slows aging | Untested | Cell-aging markers such as p16, p21, p53 and the sirtuins moved in cells in a dish (Khavinson et al., 2014; Myakisheva et al., 2023b). We found no study of lifespan or a health outcome in any animal or person |
| It switches genes on and off | Mixed | Gene activity changed in cells in three lab studies (Ashapkin et al., 2020; Myakisheva et al., 2023a; Khavinson et al., 2014). The idea that it binds DNA rests on computer models, and we found no direct test in a living body |
| It is safe, with no side effects | Untested | We found no safety study in people. The authors of an old-rat kidney study saw no sign of kidney toxicity (Zamorskii et al., 2018), and in human stem cells it raised an inflammation gene (Ashapkin et al., 2020). No reports isn’t a safety record |
| Injection schedules online come from research | Untested | The only amounts in the studies we found are concentrations in dishes, such as 200 ng/ml (Myakisheva et al., 2023a). The rat abstracts give no dose or route, and we found no study of AED injected into a person |
| It works better stacked with other peptides | Untested | No study tested it with BPC-157, TB-500 or any peptide sold for joints. Mixes of the group’s own short peptides were tested in cells, which don’t separate out AED (Caputi et al., 2019) |
| Cartalax is the same as Epitalon | Contradicted | No. Epitalon is AEDG, four amino acids, and Cartalax is AED, three; the developers’ own table lists them as separate peptides (Khavinson et al., 2021) |
| Russian research has proven it works | Mixed | There are ten studies, in cells and rats, and every one lists Linkova, Khavinson or both as an author. We found none in people and none from an independent group (Myakisheva et al., 2023a; Zamorskii et al., 2018) |
| It is FDA-approved | Contradicted | No. The FDA’s approved-drug data return no product under the names Cartalax or alanyl-glutamyl-aspartic acid (openFDA Drugs@FDA), and its safety-risk and compounding lists don’t include it |
Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.
Cartalax, Epitalon and Sigumir
| Cartalax (AED) | Epitalon (AEDG) | Sigumir (cartilage extract) | |
|---|---|---|---|
| What it is | Three amino acids | Four: AED plus glycine | A mix of short peptides from animal cartilage, AED one of them (Linkova et al., 2023) |
| Made by | The St. Petersburg Institute of Bioregulation and Gerontology group | The same group | The same institute |
| In people | No study found | Small studies; see the Epitalon page | A 2012 report of 62 patients with jaw-joint disease (Iordanishvili et al., 2012) |
| Status | Not an approved drug | Not an approved drug | Said to be in phase 2 trials in Russia; no registry record found |
For the rest of the family, see the peptide bioregulators page.
What the studies used
| Study | What was tested | Amount in the abstract |
|---|---|---|
| Myakisheva et al., 2023a | Aged human stem cells in a dish | 200 ng/ml for AED (about 600 nanomolar by our arithmetic); 2,000 ng/ml for the whole cartilage extract |
| Ashapkin et al., 2020 | Human embryo bone-marrow stem cells | “Nanomolar concentrations” |
| Lin'kova et al., 2016; Fridman et al., 2020; Khavinson et al., 2014; Chalisova et al., 2015 | Skin and kidney cells | Not stated in the abstracts |
| Zamorskii et al., 2015; Zamorskii et al., 2018 | Rats | No dose or route in the abstracts |
A concentration in a dish isn’t a dose for a person, and no study converts one into the other. We found no dose-finding or blood-level study of AED in any animal or person. These are amounts from studies, not advice for anyone to use.
Side effects and safety
- In rats. The authors of the old-rat kidney study saw no sign of kidney toxicity (Zamorskii et al., 2018).
- In cells. In human stem cells, AED raised activity of the NF-kB gene, a switch that drives inflammation. The abstract reports only that gene activity rose; what that means in a person isn’t known (Ashapkin et al., 2020).
- In people. We found no safety study, and no report of side effects, because we found no study.
- What is in the bottle. We found no independent analysis of Cartalax vials, capsules or drops.
- Not studied. Pregnancy, children, long-term use, other medicines, and any amount in people.
Side effects people report from online products aren’t covered here; they come from users, not studies.
Legal and approval status
- Not an approved drug. The FDA’s approved-drug data return no product under its names (openFDA Drugs@FDA).
- Not on the FDA’s lists. It isn’t on the safety-risk page or in the May 2026 compounding categories (FDA, 2026; FDA list, May 2026). That is not an approval.
- No registered trial. ClinicalTrials.gov lists no study of it (ClinicalTrials.gov search).
- Not in the October 2026 HHS policy. That temporary policy covers six other peptides (Reuters, 2026).
- Not named on the World Anti-Doping Agency’s 2026 list (WADA, 2026).
- “Research use only” vials and any use in people aren’t approved.
What to look for if you research it
We don’t name or link sellers. These checks come from the studies and registries:
- The letters. Cartalax is AED, three amino acids. A page that writes it as AEDG has named Epitalon (Khavinson et al., 2021).
- Whose study. Every study of AED we found lists Linkova, Khavinson or both as an author. Ask whether a claim comes from a paper or from another page repeating one.
- A dish isn’t a body. Most of the evidence is cells; check whether a “benefit” was measured in a person, an animal or a dish.
- Cartilage-specific. The studies tested it in skin, kidney and stem cells too, so the label describes what it was designed for, not what the studies show.
- Not for injection. There is no study of it in people by any route.
Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite.
What’s still unknown
- Whether Cartalax does anything for cartilage, joint pain or arthritis in people.
- Whether anyone outside the developers’ group gets the same results.
- Whether it is safe, by any route, in people.
- What amount, if any, would matter in a body, as opposed to a dish.
- What the 2023 review’s osteoarthritis patients actually took, and how they compared with anyone.
Retracted and flagged studies
A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.
We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention Cartalax. We recheck every month. Last checked Nov 12, 2026.
We found no retracted, withdrawn or flagged studies that mention Cartalax.
Studies this page relies on
| Study | Published in | Status |
|---|---|---|
| Iordanishvili et al., 2012 | Adv Gerontol | No retraction or concern |
| Khavinson et al., 2014 | Adv Gerontol | No retraction or concern |
| Chalisova et al., 2015 | Bull Exp Biol Med | No retraction or concern |
| Zamorskii et al., 2015 | Bull Exp Biol Med | No retraction or concern |
| Lin'kova et al., 2016 | Bull Exp Biol Med | No retraction or concern |
| Zamorskii et al., 2018 | Adv Gerontol | No retraction or concern |
| Caputi et al., 2019 | Int J Immunopathol Pharmacol | No retraction or concern |
| Ashapkin et al., 2020 | Mol Biol Rep | No retraction or concern |
| Fridman et al., 2020 | Bull Exp Biol Med | No retraction or concern |
| Khavinson et al., 2021 | Molecules | No retraction or concern |
| Linkova et al., 2023 | Int J Mol Sci | No retraction or concern |
| Myakisheva et al., 2023 | Adv Gerontol | No retraction or concern |
| Myakisheva et al., 2023 | Adv Gerontol | No retraction or concern |
| Myakisheva et al., 2023 | Adv Gerontol | No retraction or concern |
Bring your questions to other researchers
Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.
Questions
What is Cartalax?
A lab-made peptide of three amino acids, alanine, glutamic acid and aspartic acid (AED), made by Vladimir Khavinson’s group (PubChem; Khavinson et al., 2021).
What is Cartalax peptide good for?
It is sold for joints and cartilage, but we found no study of it in a person. The studies measured cartilage-protein genes, skin-cell markers and kidney function in cells and rats (Myakisheva et al., 2023a; Zamorskii et al., 2018).
Does Cartalax work?
It is unproven. We found ten studies, in cells and rats, all with Linkova, Khavinson or both as authors, and none in people (Myakisheva et al., 2023a; Zamorskii et al., 2015).
Can Cartalax regrow cartilage?
Not shown. We found no study that measured cartilage after it. Raising cartilage-protein markers in stem cells in a dish isn’t regrowth (Myakisheva et al., 2023a).
Is Cartalax safe?
No safety study in people exists that we could find. The authors of an old-rat kidney study saw no sign of kidney toxicity, and in human stem cells it raised an inflammation gene (Zamorskii et al., 2018; Ashapkin et al., 2020).
What are the side effects of Cartalax?
Unknown. No study in people reported any, because we found no study in people. Side effects people report from online products come from users, not studies.
What is the Cartalax dosage?
We don’t give dosing advice. The amounts in the studies are concentrations in dishes, such as 200 ng/ml, which isn’t a dose (Myakisheva et al., 2023a). We found no human dose study.
Can you inject Cartalax?
We found no study of AED injected into a person. The abstracts of the two rat studies don’t state a route (Zamorskii et al., 2015; Zamorskii et al., 2018).
Does Cartalax come as capsules or drops?
It is sold in those forms. We found no study of any form in people; a 2023 review by the developers’ group says older osteoarthritis patients took it by mouth but cites no trial (Myakisheva et al., 2023c).
What is the difference between Cartalax and Epitalon?
Cartalax is AED, three amino acids. Epitalon is AEDG, four. Some pages write Cartalax as AEDG by mistake. See the Epitalon page (Khavinson et al., 2021).
What is the difference between Cartalax and Sigumir?
Sigumir is an extract from animal cartilage made of many short peptides, with AED one of them. Cartalax is AED alone (Linkova et al., 2023).
How does Cartalax compare with BPC-157?
They are different peptides with different records. Cartalax has cell and rat studies from one group and none in people; see the BPC-157 page for its record.
Is Cartalax FDA approved or legal?
It isn’t an approved drug, and the FDA’s approved-drug data return no product under its names (openFDA Drugs@FDA). Our guide to what to look for covers the routes people use.
Who has studied Cartalax?
We found ten studies, in cells and rats, mostly in the Bulletin of Experimental Biology and Medicine and Advances in Gerontology. Each lists Linkova, Khavinson or both as an author, and we found no independent repeat (Lin'kova et al., 2016).
Sources
- Myakisheva SN, et al. [The influence of peptides on the chondrogenic differentiation of human mesenchymal stem cells during replicative aging.]. Adv Gerontol. 2023;36(3):383-390. In Russian. PubMed 37782646
- Myakisheva SN, et al. [Peptides prevent the forming of secretory phenotype of chondrocytes associated with the aging.]. Adv Gerontol. 2023;36(2):234-238. In Russian. PubMed 37356100
- Myakisheva SN, et al. [Chondrocytes secretory phenotype associated with aging: role in the pathogenesis of osteoarthritis and prospects for peptide bioregulation.]. Adv Gerontol. 2023;36(3):313-323. In Russian. PubMed 37782637
- Fridman NV, et al. Comparison of the Effects of KE and AED Peptides on Functional Activity of Human Skin Fibroblasts during Their Replicative Aging. Bull Exp Biol Med. 2020;170(1):154-157. PubMed 33231794
- Lin'kova NS, et al. Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro. Bull Exp Biol Med. 2016;161(1):175-8. PubMed 27259496
- Ashapkin V, et al. Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Mol Biol Rep. 2020;47(6):4323-4329. PubMed 32399807
- Chalisova NI, et al. Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals. Bull Exp Biol Med. 2015;159(1):124-7. PubMed 26033601
- Khavinson VKh, et al. [Tripeptides slow down aging process in renal cell culture]. Adv Gerontol. 2014;27(4):651-6. In Russian. PubMed 25946838
- Zamorskii II, et al. Peptides Restore Functional State of the Kidneys During Cisplatin-Induced Acute Renal Failure. Bull Exp Biol Med. 2015;159(6):736-9. PubMed 26515176
- Zamorskii II, et al. [The influence of peptides on the morphofunctional state of old rats kidneys.]. Adv Gerontol. 2018;31(4):498-504. In Russian. PubMed 30607912
- Caputi S, et al. Effect of short peptides on neuronal differentiation of stem cells. Int J Immunopathol Pharmacol. 2019;33:2058738419828613. PubMed 30791821
- Khavinson VK, et al. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PubMed 34834147
- Linkova N, et al. Peptide Regulation of Chondrogenic Stem Cell Differentiation. Int J Mol Sci. 2023;24(9):8415. PubMed 37176122
- Iordanishvili AK, et al. [Application of bioregulating therapy in complex treatment of temporomandibular joint diseases in people of elderly and senile age]. Adv Gerontol. 2012;25(1):181-6. In Russian. PubMed 22708467
- ClinicalTrials.gov. Search for Cartalax, AED peptide and Ala-Glu-Asp, November 12, 2026: no study of it. Search
- U.S. Food and Drug Administration. openFDA Drugs@FDA: searches for Cartalax, Ala-Glu-Asp and alanyl-glutamyl-aspartic acid, November 12, 2026: no match. openFDA
- U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. Content current as of April 22, 2026. FDA page
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A. Updated May 14, 2026. FDA document
- World Anti-Doping Agency. 2026 Prohibited List. WADA document
- Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
- National Library of Medicine. PubChem compound record: Cartalax (Ala-Glu-Asp) (CID 87815447). PubChem
Last reviewed Nov 12, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.